Lupin falls; Mylan launches cholesterol drug
Reuters Market Eye - Shares in Lupin Ltd (LUPN.NS) slump 4 percent after earlier falling as much as 4.7 percent following the launch of rival Mylan Inc's (MYL.O) generic version of the cholesterol-lowering Tricor tablets.
Mylan Inc said in a statement on Friday its unit Mylan Pharmaceuticals Inc has shipped generic Tricor, or fenofibrate tablets, of 48 mg and 145 mg.
Mylan compete against Lupin, which also sells generic versions of Tricor.
"Mylan's launch of Tricor will result in higher competition and decline in Lupin's market share in a drug which has a market size of $1.2 billion," said Ranjit Kapadia, senior vice president at Centrum Broking.
(Reporting by Abhishek Vishnoi)
- Tweet this
- Share this
- Digg this
- UPDATE 3-Turkish president rejects Facebook, YouTube ban over wiretaps
- UPDATE 1-"Everything is fine", Pistorius told guard after shooting girlfriend
- Exclusive - Pimco's Gross declares El-Erian is 'trying to undermine me'
- UPDATE 3-MasterCard, Visa form group to push for better card security
- UPDATE 3-Ted Turner rushed to clinic in Argentina with appendicitis-media
Sahara’s investment programmes include schemes that are similar to a typical Indian bank’s fixed or recurring deposits. But the arrest of the company's chief Subrata Roy last week and the court case over an outlawed bond scheme are raising fears among some investors who worry they will not get their money back. Full Article